PL394601A1 - Sól estru etylowego kwasu 3-[(2-{[4-(heksylooksykarbonyloaminoiminometylo)-fenyloamino]metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-yloamino]propionowego oraz kompozycja farmaceutyczna ją zawierająca - Google Patents

Sól estru etylowego kwasu 3-[(2-{[4-(heksylooksykarbonyloaminoiminometylo)-fenyloamino]metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-yloamino]propionowego oraz kompozycja farmaceutyczna ją zawierająca

Info

Publication number
PL394601A1
PL394601A1 PL394601A PL39460103A PL394601A1 PL 394601 A1 PL394601 A1 PL 394601A1 PL 394601 A PL394601 A PL 394601A PL 39460103 A PL39460103 A PL 39460103A PL 394601 A1 PL394601 A1 PL 394601A1
Authority
PL
Poland
Prior art keywords
methyl
hexyloxycarbonylaminoiminomethyl
benzimidazol
ylamino
phenylamino
Prior art date
Application number
PL394601A
Other languages
English (en)
Other versions
PL212566B1 (pl
Inventor
Ulrich Brauns
Norbert Hauel
Peter Sieger
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27789735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL394601(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10209985A external-priority patent/DE10209985A1/de
Priority claimed from DE2002145624 external-priority patent/DE10245624A1/de
Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg
Publication of PL394601A1 publication Critical patent/PL394601A1/pl
Publication of PL212566B1 publication Critical patent/PL212566B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL394601A 2002-03-07 2003-03-03 Sól estru etylowego kwasu 3-[(2-{[4-(heksylooksykarbonyloaminoiminometylo) fenyloamino]metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-yloamino]propionowego PL212566B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10209985A DE10209985A1 (de) 2002-03-07 2002-03-07 Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze
DE2002145624 DE10245624A1 (de) 2002-09-30 2002-09-30 Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2yl-amino]-propinsäure-ethylester und dessen Salze

Publications (2)

Publication Number Publication Date
PL394601A1 true PL394601A1 (pl) 2011-07-18
PL212566B1 PL212566B1 (pl) 2012-10-31

Family

ID=27789735

Family Applications (2)

Application Number Title Priority Date Filing Date
PL394601A PL212566B1 (pl) 2002-03-07 2003-03-03 Sól estru etylowego kwasu 3-[(2-{[4-(heksylooksykarbonyloaminoiminometylo) fenyloamino]metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-yloamino]propionowego
PL370517A PL210862B1 (pl) 2002-03-07 2003-03-03 Kompozycja farmaceutyczna w postaci peletki do doustnego podawania i sposób wytwarzania kompozycji

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL370517A PL210862B1 (pl) 2002-03-07 2003-03-03 Kompozycja farmaceutyczna w postaci peletki do doustnego podawania i sposób wytwarzania kompozycji

Country Status (36)

Country Link
US (2) US20190231766A1 (pl)
EP (2) EP1870100B1 (pl)
JP (3) JP3866715B2 (pl)
KR (1) KR101005716B1 (pl)
CN (1) CN100528157C (pl)
AR (2) AR042861A1 (pl)
AT (1) ATE540943T1 (pl)
AU (1) AU2003210400B8 (pl)
BR (1) BRPI0306559B8 (pl)
CA (1) CA2476054C (pl)
CL (1) CL2009001915A1 (pl)
CO (1) CO5611149A2 (pl)
CY (4) CY1112796T1 (pl)
DE (1) DE122012000047I1 (pl)
DK (2) DK1485094T4 (pl)
EA (1) EA009664B1 (pl)
EC (1) ECSP045331A (pl)
ES (2) ES2380704T3 (pl)
HK (1) HK1078792A1 (pl)
HR (1) HRP20040807B1 (pl)
IL (3) IL163863A0 (pl)
LU (2) LU92025I2 (pl)
ME (1) ME00325B (pl)
MX (1) MXPA04008542A (pl)
MY (1) MY143734A (pl)
NO (3) NO326918B1 (pl)
NZ (2) NZ546367A (pl)
PE (1) PE20030889A1 (pl)
PL (2) PL212566B1 (pl)
PT (2) PT1485094E (pl)
RS (1) RS52088B (pl)
SG (1) SG146435A1 (pl)
SI (2) SI1870100T1 (pl)
TW (1) TWI293879B (pl)
WO (1) WO2003074056A1 (pl)
ZA (1) ZA200406071B (pl)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20050070537A1 (en) 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
DE10341043A1 (de) * 2003-09-03 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue oral zu applizierende Darreichungsform für 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen Salze
US20070298095A1 (en) * 2004-05-24 2007-12-27 Shionogi Qualicaps Co., Ltd. Surface-Modified and Solubility-Improved Hard Capsule
DE102004062864A1 (de) 2004-12-21 2006-06-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Folienbehälter
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
DE102005025728A1 (de) 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102005061623A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
DE102005061624A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen
EA200900091A1 (ru) * 2006-07-17 2009-06-30 Бёрингер Ингельхайм Интернациональ Гмбх Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
JP2009543844A (ja) * 2006-07-17 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 直接トロンビン阻害剤の新しい小児適応症
EP2074112A1 (en) * 2006-10-10 2009-07-01 Boehringer Ingelheim International GmbH Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
CN101980697A (zh) * 2008-03-28 2011-02-23 贝林格尔.英格海姆国际有限公司 制备口服给药的达比加群制剂的方法
US20120276206A1 (en) * 2008-03-28 2012-11-01 Boehringer Ingelheim International Gmbh Method for manufacturing acid pellets
KR20110039261A (ko) * 2008-07-14 2011-04-15 베링거 인겔하임 인터내셔날 게엠베하 다비가트란을 함유하는 의료용 화합물의 제조 방법
US9186411B2 (en) 2008-07-28 2015-11-17 Takeda Pharmaceutical Company Limited Pharmaceutical composition
WO2010020600A1 (en) * 2008-08-19 2010-02-25 Boehringer Ingelheim International Gmbh Use of dabigatranetexilate for treating patients with pulmonary hypertension
JP2012500245A (ja) * 2008-08-19 2012-01-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 経皮的インターベンション心臓カテーテル法のためのダビガトラン
JP2012526766A (ja) 2009-05-14 2012-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍性及び線維性疾患の処置における新規な併用療法
AU2010288601A1 (en) 2009-08-24 2012-02-02 Boehringer Ingelheim International Gmbh Emergency interventions of active charcoal with dabigatran etexilate overdosing
PL2542224T3 (pl) * 2010-03-01 2014-12-31 Ratiopharm Gmbh Doustna kompozycja farmaceutyczna zawierająca eteksylan dabigatranu
EA201201263A1 (ru) 2010-03-08 2013-04-30 Рациофарм Гмбх Фармацевтическая композиция, содержащая этексилат дабигатрана
US20130177652A1 (en) 2010-07-01 2013-07-11 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
MX2013000295A (es) 2010-07-09 2013-05-28 Esteve Quimica Sa Procedimiento de preparacion de un inhibidor especifico de la trombina.
CN103025715A (zh) 2010-07-09 2013-04-03 埃斯特维化学股份有限公司 用于制备凝血酶特异性抑制剂的中间体和方法
EP2603503B1 (en) 2010-09-27 2015-08-05 ratiopharm GmbH Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof
EA201391758A1 (ru) * 2011-05-24 2014-06-30 Тева Фармасьютикал Индастриз Лтд. Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты
CN102391250B (zh) * 2011-08-29 2013-06-19 石药集团欧意药业有限公司 一种达比加群酯化合物、制备方法及其药物组合物
CN103998024A (zh) * 2011-12-22 2014-08-20 勃林格殷格翰国际有限公司 速释多单元微丸系统
US9212166B2 (en) 2012-01-20 2015-12-15 Cadila Healthcare Limited Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof
WO2013110567A1 (en) 2012-01-24 2013-08-01 Boehringer Ingelheim International Gmbh Novel orally administered dabigatran formulation
EP3858337A3 (en) * 2012-02-21 2021-09-29 Towa Pharmaceutical Europe, S.L. Oral pharmaceutical compositions of dabigatran etexilate
EP2631234A1 (en) 2012-02-23 2013-08-28 Esteve Química, S.A. Solid forms of dabigatran etexilate mesylate and processes for their preparation
WO2013144971A1 (en) 2012-03-27 2013-10-03 Cadila Healthcare Limited New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them
US9273030B2 (en) 2012-04-02 2016-03-01 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and salts thereof
WO2014001220A1 (en) 2012-06-25 2014-01-03 Boehringer Ingelheim International Gmbh Method for prevention of stroke
EP2900652A2 (en) 2012-09-28 2015-08-05 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
IN2015DN02616A (pl) 2012-09-28 2015-09-18 Ranbaxy Lab Ltd
WO2014060561A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral pharmaceutical formulations comprising dabigatran
EP2722033A1 (en) 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical Compositions of Dabigatran Free Base
EP2740471B1 (en) 2012-12-07 2015-05-27 Hexal AG Oral pharmaceutical composition comprising dabigatran etexilate
CN103127109B (zh) * 2013-02-05 2014-08-13 南京华威医药科技开发有限公司 含达比加群酯或其盐和水合物的药用组合
EP2835370A1 (en) 2013-08-08 2015-02-11 Medichem, S.A. New crystals of dabigatran etexilate mesylate
CN104414995A (zh) * 2013-09-04 2015-03-18 天津汉瑞药业有限公司 甲磺酸达比加群酯的药用组合物
EP2853260A1 (en) 2013-09-27 2015-04-01 ratiopharm GmbH Pharmaceutical preparation comprising dabigatran etexilate bismesylate
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
IN2014MU01042A (pl) 2014-03-26 2015-10-02 Cadila Healthcare Ltd
WO2015155281A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of dabigatran and proton pump inhibitors
EP2929884A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and h2-receptor antagonists
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105764509B (zh) * 2014-11-03 2019-03-19 杭州领业医药科技有限公司 达比加群酯或其盐的投药制剂及其制备方法
CN105640909B (zh) * 2014-11-14 2019-09-20 正大天晴药业集团股份有限公司 一种含有达比加群酯的药用组合物
EP4205743A1 (en) 2014-12-31 2023-07-05 Shenzhen Pharmacin Co., Ltd. Pharmaceutical composition and preparation method therefor
CN105797162B (zh) * 2014-12-31 2022-10-25 昆明积大制药股份有限公司 药用辅料表面改性方法
CN106924256B (zh) * 2015-12-25 2022-08-19 深圳市药欣生物科技有限公司 药物组合物及其制备方法
TR201502223A2 (tr) 2015-02-25 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dronedaron ve dabigatranın farmasötik kombinasyonları.
CN106999434B (zh) * 2015-04-08 2020-05-22 杭州领业医药科技有限公司 一种含半胱氨酸盐酸盐的微丸及其制备方法
WO2017013106A1 (en) 2015-07-20 2017-01-26 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical formulations of dabigatran free base
CN105919962B (zh) * 2015-12-18 2019-01-18 重庆两江药物研发中心有限公司 一种达比加群酯片剂及其制备方法
EP3184102A1 (en) 2015-12-23 2017-06-28 Hexal AG Pharmaceutical composition of vortioxetine hydrobromide comprising an inert core formed of an acidic reacting compound
WO2017111637A1 (en) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TR201606697A2 (tr) 2016-05-20 2017-12-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin yeni̇ oral farmasöti̇k formülasyonlari
EP3332771A1 (en) 2016-12-07 2018-06-13 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayered tablet compositions of dabigatran
TR201617984A2 (tr) 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin farmasöti̇k kompozi̇syonlari
EP3342401A1 (en) 2016-12-28 2018-07-04 Sanovel Ilac Sanayi ve Ticaret A.S. Bilayer tablet formulations of dabigatran etexilate
JP2018184375A (ja) 2017-04-27 2018-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ダビガトランエテキシラート又は医薬的に許容されるその塩を含む錠剤及びその製造方法
WO2018229784A1 (en) * 2017-06-14 2018-12-20 Natco Pharma Limited Pharmaceutical compositions of dabigatran
CN109125274A (zh) * 2017-06-28 2019-01-04 上海美悦生物科技发展有限公司 注射用苯并咪唑类药用酸组合物及其制备方法和用途
TR201722323A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari
TR201722186A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin farmasöti̇k kompozi̇syonlari
TR201722353A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatran eteksi̇lat i̇çeren oral uygulama i̇çi̇n farmasöti̇k formülasyon
TR201722630A2 (pl) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
CN110339193B (zh) 2018-04-04 2022-04-29 上海汉都医药科技有限公司 含达比加群酯的药物组合物及其制备方法
KR20200082641A (ko) 2018-12-31 2020-07-08 주식회사 유영제약 다비가트란 에텍실레이트를 포함하는 약제학적 조성물
EP3771465A1 (en) 2019-08-01 2021-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising dabigatran etexilate
KR20210157692A (ko) 2020-06-22 2021-12-29 한국유나이티드제약 주식회사 다비가트란 에텍실레이트를 포함하는 경구용 약학조성물
KR20210157693A (ko) 2020-06-22 2021-12-29 한국유나이티드제약 주식회사 다비가트란 에텍실레이트를 포함하는 경구용 약학조성물
KR20210157691A (ko) 2020-06-22 2021-12-29 한국유나이티드제약 주식회사 다비가트란 에텍실레이트를 포함하는 경구용 약학조성물
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
CN115227663B (zh) * 2021-04-22 2023-12-12 石药集团恩必普药业有限公司 一种甲磺酸达比加群酯胶囊及其制备方法
WO2023139243A1 (en) 2022-01-21 2023-07-27 Adamed Pharma S.A A process for preparation of tartaric acid cores for dabigatran pellets and the pellets containing dabigatran
GR1010399B (el) * 2022-04-05 2023-02-03 Φαρματεν Α.Β.Ε.Ε., Φαρμακευτικο σκευασμα που περιλαμβανει εναν αντιπηκτικο παραγοντα και μεθοδος παραγωγης αυτου

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS58134033A (ja) * 1982-02-02 1983-08-10 Fujisawa Pharmaceut Co Ltd 医薬組成物
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
DE10133786A1 (de) * 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis

Also Published As

Publication number Publication date
HRP20040807A2 (en) 2005-02-28
CY2012031I1 (el) 2015-08-05
DK1485094T4 (da) 2020-06-22
ATE540943T1 (de) 2012-01-15
BRPI0306559B1 (pt) 2021-05-18
JP3866715B2 (ja) 2007-01-10
SI1870100T1 (sl) 2012-05-31
ES2390661T5 (es) 2020-12-04
ES2380704T9 (es) 2013-07-24
RS52088B (sr) 2012-06-30
LU92025I2 (fr) 2012-08-20
AU2003210400B2 (en) 2008-08-07
KR20040099298A (ko) 2004-11-26
IL163863A (en) 2013-02-28
CY2012020I1 (el) 2015-08-05
AU2003210400B8 (en) 2008-09-25
CN100528157C (zh) 2009-08-19
CN1638771A (zh) 2005-07-13
PL212566B1 (pl) 2012-10-31
CL2009001915A1 (es) 2010-02-12
HRP20040807B1 (hr) 2014-11-21
NO332209B1 (no) 2012-07-30
NO20042361D0 (no) 2004-06-07
RS79204A (en) 2007-02-05
EP1485094B1 (de) 2012-07-04
CA2476054C (en) 2011-11-08
EP1870100A1 (de) 2007-12-26
DK1485094T3 (da) 2012-10-15
CY1113158T1 (el) 2015-08-05
PT1870100E (pt) 2012-04-17
NO2013001I1 (no) 2013-02-11
CA2476054A1 (en) 2003-09-12
JP2006328081A (ja) 2006-12-07
EP1485094A1 (de) 2004-12-15
ES2390661T3 (es) 2012-11-15
MXPA04008542A (es) 2004-12-06
NZ535663A (en) 2006-06-30
JP4953727B2 (ja) 2012-06-13
SG146435A1 (en) 2008-10-30
US20200085807A1 (en) 2020-03-19
TWI293879B (en) 2008-03-01
ZA200406071B (en) 2005-11-30
AU2003210400A1 (en) 2003-09-16
CY2012031I2 (el) 2015-08-05
SI1485094T2 (sl) 2020-08-31
BR0306559A (pt) 2004-11-30
CY2012020I2 (el) 2015-08-05
ES2380704T3 (es) 2012-05-17
AR042861A1 (es) 2005-07-06
PT1485094E (pt) 2012-10-09
CO5611149A2 (es) 2006-02-28
PL370517A1 (pl) 2005-05-30
AR072385A2 (es) 2010-08-25
IL209368A0 (en) 2011-01-31
MEP50708A (en) 2011-02-10
DK1870100T3 (da) 2012-05-14
MY143734A (en) 2011-07-15
NO2013001I2 (no) 2014-09-01
JP2007056018A (ja) 2007-03-08
EA009664B1 (ru) 2008-02-28
ME00325B (me) 2011-05-10
CY1112796T1 (el) 2015-08-05
IL163863A0 (en) 2005-12-18
DE122012000047I1 (de) 2012-09-13
HK1078792A1 (en) 2006-03-24
NO20081304L (no) 2004-06-07
EA200401136A1 (ru) 2005-04-28
NO326918B1 (no) 2009-03-16
EP1870100B1 (de) 2012-01-11
PE20030889A1 (es) 2003-12-10
IL209368A (en) 2012-10-31
JP2005519099A (ja) 2005-06-30
NZ546367A (en) 2008-08-29
KR101005716B1 (ko) 2011-01-05
PL210862B1 (pl) 2012-03-30
TW200306188A (en) 2003-11-16
EP1485094B2 (de) 2020-03-25
NO20042361L (no) 2004-06-07
SI1485094T1 (sl) 2012-10-30
ECSP045331A (es) 2006-04-19
WO2003074056A1 (de) 2003-09-12
BRPI0306559B8 (pt) 2021-05-25
LU92117I2 (fr) 2013-02-19
US20190231766A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
PL394601A1 (pl) Sól estru etylowego kwasu 3-[(2-{[4-(heksylooksykarbonyloaminoiminometylo)-fenyloamino]metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-yloamino]propionowego oraz kompozycja farmaceutyczna ją zawierająca
DK1658056T3 (da) Tabletter indeholdende 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionsyreethylester eller salte deraf
HK1257298A1 (zh) 硼的酯和酸化合物的合成
PL1660482T3 (pl) Metanosulfonian 3-[(2-{[4-(heksyloksykarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionianu etylu i jego zastosowanie jako leku
IL172875A0 (en) Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
EP1801096A4 (en) POLYGLYCERIN FUEL ACID AND THE COMPOSITIONS CONTAINING THEREOF
HUP0303810A3 (en) Carboxylic acid derivative and salt thereof and pharmaceutical compositions containing them
DK1488790T3 (da) Fast præparat indeholdende en enkeltkrystalform A af etthiazolcarboxylsyrederivat
EP1578949A3 (en) Site specific incorporation of keto amino acids into proteins
HK1102348A1 (en) Composition containing polyglycerol/medium-chain fatty acid ester
IL170316A (en) Cycloalkyl-methoxy substituted acetic acid derivatives and pharmaceutical compositions comprising them
HUP0203444A3 (en) Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid, process for its preparation, pharmaceutical composition containing it and use thereof
AU2003225651A1 (en) Nematicidal fatty acid and fatty acid ester related compounds
IL174248A0 (en) Alkyl carboxylic acid derivatives and pharmaceutical compositions containing the same
AU2003222083A1 (en) Acid and ester compounds and methods of using the same
EP1633328A4 (en) METHOD AND COMPOSITION FOR STABLE AND CONTROLLED ADMINISTRATION OF (-) - HYDROXYCITRIC ACID
AU2003282178A1 (en) Novel method for the industrial synthesis of the methyl diester of 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid and application of divalent salts of ranelic acid and the hydrates thereof in said synthesis
AU2003201911A1 (en) Method of preventing clogging of apparatus for handling (meth)acrylic acid and ester thereof
AU2003215947A1 (en) Controlled release composition comprising felodipine and method of preparation thereof
AU2003224144A1 (en) Method for the production of acrylic acid and/or the esters thereof and propionic acid and/or the esters thereof in a compound
IS7056A (is) Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3 [4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxý própansýru og insúlín
PL370962A1 (pl) Nowe estry etylowe kwasu (2'-izopropenylo-5'-metylo-1'-cykloheksylideno)-octowego i sposób ich otrzymywania
AU2003203174A1 (en) Metal salts of (3s)-3-methoxycarbonyl-4-phenylbutyric acid and usage thereof
DE60209436D1 (de) Alkyl Ester der 2-(2-Fluorosulfonyl)-perfluoroethylenoxy-3-halogen-Propionsäure
GB0415097D0 (en) Formulation containing a carboxylic acid or an ester thereof